Skip to main content
GNLX
NASDAQ Life Sciences

Genelux Q2 Loss Widens to $9.5M; Phase 3 Ovarian Cancer Data Due 2H26

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$2.63
Mkt Cap
$117.93M
52W Low
$2.29
52W High
$8.535
52W Position info
15% above low
Off High info
69% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

GNLX is trading near its 52-week low of $2.29 (15% above the low).

Summary

Genelux reported Q2 results with a net loss of $9.5 million, wider than expected, driven by higher Phase 3 trial costs and R&D expenses. Cash and equivalents totaled $18.7 million as of June 30, 2026, expected to fund operations into Q1 2027. The company reiterated that topline data from the Phase 3 OnPrime/GOG-3076 trial in platinum-resistant/refractory ovarian cancer is anticipated in the second half of 2026. Additional dose-escalation updates from systemic lung cancer programs are expected in 2026. The going concern warning remains in place, consistent with the 10-Q filed earlier today.

At the time of this announcement, GNLX was trading at $2.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $117.9M. The 52-week trading range was $2.29 to $8.54. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

GNLX - Latest Insights

GNLX
Nov 16, 2026, 4:23 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.88
Real-time Price: $2.32 info
Change: +$0.440 (+23%) info
Market Cap: $109.586M info
GNLX
Nov 16, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.88
Real-time Price: $2.32 info
Change: +$0.440 (+23%) info
Market Cap: $109.586M info
GNLX
Sep 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.52
Real-time Price: $2.32 info
Change: -$0.200 (-8%) info
Market Cap: $109.586M info
GNLX
Aug 13, 2026, 1:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.75
Real-time Price: $2.32 info
Change: -$0.430 (-16%) info
Market Cap: $109.586M info
GNLX
May 07, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.83
Real-time Price: $2.32 info
Change: -$0.510 (-18%) info
Market Cap: $109.586M info